Picture of Pulse Biosciences logo

PLSE Pulse Biosciences News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapMomentum Trap

Pulse Biosciences Inc expected to post a loss of 69 cents a share - Earnings Preview

* Pulse Biosciences Inc  PLSE.OQ   PLSE.O  is expected to show a
rise in quarterly revenue when it reports results on August 9. 
* The Hayward, California-based company is expected to report
revenue of $34 thousand, according to the mean estimate from 3
analysts, based on Refinitiv data.  
​* Refinitiv's mean analyst estimate for Pulse Biosciences Inc
is for a loss of 69 cents per share. For the same quarter last
year, the company reported a loss of 53 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Pulse
Biosciences Inc is $40​, about 42.8% above​ its last closing
price of $22.90. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.49       -0.49      -0.71     Missed  -43.4
 Dec. 31 2020  -0.45       -0.45      -0.54     Missed  -20
 Sep. 30 2020  -0.44       -0.44      -0.51     Missed  -15.9​
 Jun. 30 2020  -0.50       -0.50      -0.53     Missed  -6
 Mar.          -0.47​      -0.47      -0.57     Missed  -21.3​
 31​ 2020​                                              
 Dec. 31 2019              -0.61      -0.66     Missed  -8.2​
 Sep. 30 2019  -0.61       -0.61      -0.57     Beat    6.6
 Jun. 30 2019  -0.51       -0.51      -0.55     Missed  -7.8
 This summary was machine generated August 6 at 23:10 GMT.  All
figures in US dollars unless otherwise stated

Recent news on Pulse Biosciences

See all news